Hypoxia-mediated drug resistance in breast cancers

• Published in: Cancer letters Vol. 502; pp. 189 - 199
• Main Authors: McAleese, Courtney E., Choudhury, Chandra, Butcher, Neville J., Minchin, Rodney F.
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.04.2021; Elsevier Limited
• Subjects: Autophagy; Breast cancer; Chemoresistance; Drug efflux; Drug resistance; Drug targets; Gene expression; HIF-1α induction; Hypoxia; Hypoxia-inducible factor 1a; Kinases; Localization; Metabolism; Metastases; Microvasculature; Oxygen tension; Phenotypes; Phosphorylation; Proteins; Proteomics; Solid tumors; Stemness; Transcription factors; Tumor cells; Tumors; Stemness; Drug efflux; Drug targets; HIF-1α induction; Autophagy; Chemoresistance
• ISSN: 0304-3835; 1872-7980
• DOI: 10.1016/j.canlet.2020.11.045

Tissue hypoxia in solid tumors is caused by several pathological changes associated with tumor growth, including altered microvasculature structure, increased diffusional distances, and tumor-associated anemia. As the oxygen tension decreases, tumor cells adapt to the limited oxygen supply. Previous studies have shown that such adaptation leads to an aggressive phenotype that is resistant to many anti-cancer therapies. Induction of hypoxia inducible factors (HIFs) mediates many proteomic and genomic changes associated with tumor hypoxia. In breast cancers, HIFs not only predict poor prognosis, but also promote metastasis and drug resistance. Several studies have proposed HIF-1α as a druggable target in drug-resistant breast cancers, leading to the synthesis and development of small molecule inhibitors. Disappointingly, however, none of these small molecule inhibitors have progressed to clinical use. In this review, we briefly discuss the role of HIF-1α in breast cancer drug resistance and summarize the current and future approaches to targeting this transcription factor in breast cancer treatment. •Breast cancer treatments fail due to development of drug resistance.•Solid tumors display regions of hypoxia, which express hypoxia inducible factors.•Hypoxia inducible factors promote drug resistance in breast cancers.•Resistance occurs with conventional chemotherapy, targeted chemotherapy and endocrine therapy.•Drugs developed to target hypoxia inducible factors have potential in breast cancer treatment.